argenx NV ADR (ARGX)vsBeiGene, Ltd. (ONC)
ARGX
argenx NV ADR
$783.50
+0.23%
HEALTHCARE · Cap: $48.96B
ONC
BeiGene, Ltd.
$297.14
+1.12%
HEALTHCARE · Cap: $32.66B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 26% more annual revenue ($5.34B vs $4.24B). ARGX leads profitability with a 30.5% profit margin vs 5.4%. ARGX trades at a lower P/E of 40.0x. ARGX earns a higher WallStSmart Score of 61/100 (C+).
ARGX
Buy61
out of 100
Grade: C+
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+60.4%
Fair Value
$2106.55
Current Price
$783.50
$1323.05 discount
Margin of Safety
+79.7%
Fair Value
$1726.48
Current Price
$297.14
$1429.34 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Strong operational efficiency at 27.4%
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.6x book value
Earnings declined 31.9%
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 118.5x leaves little room for execution misses.
Key Dynamics to Monitor
ARGX profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.54 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (61/100 vs 42/100), backed by strong 30.5% margins and 73.0% revenue growth. ONC offers better value entry with a 79.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?